Philippe Douville
Directeur Général chez Find Therapeutics
Profil
Philippe Douville is the founder of Milestone Pharmaceuticals, Inc. which was founded in 2005.
He held the position of President, Chief Executive Officer & Director from 2005 to 2017.
Dr. Douville is also the founder of Allostera Pharma, Inc., Galileo Genomics, Inc. He is currently the Chief Executive Officer at Find Therapeutics since 2022.
He previously worked as a Senior Analyst at eResearch Corp.
Dr. Douville received a doctorate degree from McGill University in 1991 and an MBA degree from HEC Montréal.
Postes actifs de Philippe Douville
| Sociétés | Poste | Début |
|---|---|---|
Find Therapeutics
 Find Therapeutics BiotechnologyHealth Technology Find Therapeutics develops therapeutics for inflammatory and fibrotic disease. The company is headquartered in Saint-Laurent, Canada. | Directeur Général | 14/02/2022 |
Anciens postes connus de Philippe Douville
| Sociétés | Poste | Fin |
|---|---|---|
| Galileo Genomics, Inc. | Directeur Général | - |
Allostera Pharma, Inc.
 Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Fondateur | - |
| MILESTONE PHARMACEUTICALS INC. | Directeur Général | 07/03/2017 |
eResearch Corp.
 eResearch Corp. Investment ManagersFinance eResearch Corp. is an independent investment research firm headquartered in Toronto, Canada. The firm was founded in 2000 and provides institutional-quality, equity research focused primarily on small- and mid-cap companies. Their focus is on identifying companies that have interesting prospects, sound management, and significant potential for share price appreciation. They also provide research reports on middle and larger-sized companies, through a combination of fundamental and technical analysis. eResearch complements their corporate research coverage with a diversified selection of informative, insightful, and thought-provoking research publications from a wide variety of investment professionals. | Analyst-Equity | - |
Formation de Philippe Douville
| McGill University | Doctorate Degree |
| HEC Montréal | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MILESTONE PHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
| Galileo Genomics, Inc. | |
eResearch Corp.
eResearch Corp. Investment ManagersFinance eResearch Corp. is an independent investment research firm headquartered in Toronto, Canada. The firm was founded in 2000 and provides institutional-quality, equity research focused primarily on small- and mid-cap companies. Their focus is on identifying companies that have interesting prospects, sound management, and significant potential for share price appreciation. They also provide research reports on middle and larger-sized companies, through a combination of fundamental and technical analysis. eResearch complements their corporate research coverage with a diversified selection of informative, insightful, and thought-provoking research publications from a wide variety of investment professionals. | Finance |
Allostera Pharma, Inc.
Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Distribution Services |
Find Therapeutics
Find Therapeutics BiotechnologyHealth Technology Find Therapeutics develops therapeutics for inflammatory and fibrotic disease. The company is headquartered in Saint-Laurent, Canada. | Health Technology |